Amprion’s αSyn Seed Amplification Assay (αS-SAA) Highlighted in 10 Presentations at AD/PD™ 2024 International Conference
SAN DIEGO, March 4, 2024 – Amprion is
Menu
The SYNTap Test helps physicians diagnose synucleinopathies such as: Parkinson’s, DLB, Alzheimer’s with Lewy bodies, MCI, and MSA.
This website is intended for the informational purposes of healthcare professionals.
How the SYNTap Test helps improve diagnostic accuracy for various types of Parkinson's.
How the SYNTap Test can improve the diagnostic challenges of Lewy body dementia.
How the SYNTap Test helps differentiate the Alzheimer's variant: AD with Lewy bodies.
How the SYNTap Test helps physicians differentiate MSA from Parkinson's disease.
How the SYNTap Test helps detect Minimal Cognitive Impairment with Lewy bodies early.
Details on the SYNTap Biomarker CSF Test performance characteristics.
A pioneer of Prion Detection Science®, Amprion innovates biomarker testing to accurately detect misfolded proteins associated with brain diseases.
After decades of research, Amprion is thrilled to roll out its impactful discoveries from the lab to the world.
SAN DIEGO, March 4, 2024 – Amprion is
San Diego Business Journal, February 9, 2023 Parkinson’s
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.
To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:
Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.
The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.
For additional information, please visit our billing page.
